Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Getting in on the ground floor would be great, but only if there's massive upside ahead for the company.

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...

Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...

AI is revolutionizing healthcare, with Recursion Pharmaceuticals leveraging AI and vast datasets for drug discovery, making it a compelling investment opportunity. Recursion's integrated drug ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

If you are eyeing Recursion Pharmaceuticals and wondering whether now is the time to act, you are not alone. The stock just staged a remarkable run, up 20.8% over the past week and soaring 36.0% ...